RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Intellia Therapeutics, with a price target of $9.00. The company’s shares closed yesterday at $14.28.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Issi has an average return of -2.1% and a 39.15% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intellia Therapeutics with a $15.56 average price target, implying an 8.96% upside from current levels. In a report released today, TipRanks – Google also reiterated a Hold rating on the stock with a $14.50 price target.

Based on Intellia Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $95.79 million. In comparison, last year the company earned a revenue of $12.87 million and had a GAAP net loss of $128.9 million

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year. Last month, JAMES BASTA, the EVP & GC of NTLA sold 10,397.00 shares for a total of $95,756.37.